Reuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for the experimental Alzheimer’s drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen’s stock, which lost more than $17 billion of its value on Thursday.
Investors believe the successful development of a treatment for Alzheimer’s, which affects about 5.7 million Americans, will result in multi-billion dollar annual sales. Still-experimental treatments have had a dismal track record, with more than 100 failures. The trials ended just two weeks after Eisai’s chief executive had expressed confidence in the drug. “I believe we have already gone through the riskiest stage,” Haruo Naito had said at a news briefing earlier this month.
Oops
This sucks.
Did they forget? 😂
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday. Liberals trying to think about stocks
Прочитайте больше »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open. mr_jettlife Average working class people should NEVER buy stocks. It's Gambling. The only people who make money in it are insiders and millionaires and billionaires.
Прочитайте больше »